Therapeutic potential of an AcHERV-HPV L1 DNA vaccine

Journal of Microbiology

Volumn 53, Issue 6, 2015, Pages 415-420

  Lee, Hee Jung ^a   Yoon, Jong Kwang ^a   Heo, Yoonki ^a   Cho, Hansam ^a   Cho, Yeondong ^a   Gwon, Yongdae ^a   Kim, Kang Chang ^a   Choi, Jiwon ^a   Lee, Jae Sung ^b   Oh, Yu Kyoung ^c   Kim, Young Bong ^a  

^a Konkuk University   (South Korea)

^b Kolon Life Science   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

anti tumor; cytotoxic T lymphocytes; human papillomavirus; immunity; vaccine

Indexed keywords

HUMAN ENDOGENOUS RETROVIRUS; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MUS;

CAPSID PROTEIN; DNA VACCINE; DRUG CARRIER; HPV L1 PROTEIN, HUMAN PAPILLOMAVIRUS; ONCOPROTEIN; WART VIRUS VACCINE;

ANIMAL; C57BL MOUSE; CARCINOMA; CYTOTOXIC T LYMPHOCYTE; DISEASE MODEL; ENDOGENOUS RETROVIRUS; GENETICS; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; TREATMENT OUTCOME;

ANIMALS; CAPSID PROTEINS; CARCINOMA; DISEASE MODELS, ANIMAL; DRUG CARRIERS; ENDOGENOUS RETROVIRUSES; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME; VACCINES, DNA;

EID: 84930204473     PISSN: 12258873     EISSN: 19763794     Source Type: Journal    
DOI: 10.1007/s12275-015-5150-0     Document Type: Article

References (31)

1. Bellone, S., El-Sahwi, K., Cocco, E., Casagrande, F., Cargnelutti, M., Palmieri, M., Bignotti, E., Romani, C., Silasi, D.A., Azodi, M., et al. 2009. Human papillomavirus type 16 (HPV-16) viruslike particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines. J. Virol.83, 6779–6789.
2. Bissett, S.L., Draper, E., Myers, R.E., Godi, A., and Beddows, S. 2014. Cross-neutralizing antibodies elicited by the Cervarix(R) human papillomavirus vaccine display a range of Alpha-9 intertype specificities. Vaccine32, 1139–1146.
3. Bosch, F.X., Broker, T.R., Forman, D., Moscicki, A.B., Gillison, M.L., Doorbar, J., Stern, P.L., Stanley, M., Arbyn, M., Poljak, M., et al. 2013. Comprehensive control of human papillomavirus infections and related diseases. Vaccine31 Suppl 7, H1–31.
4. Buck, C.B., Thompson, C.D., Pang, Y.Y., Lowy, D.R., and Schiller, J.T. 2005. Maturation of papillomavirus capsids. J. Virol.79, 2839–2846.
5. Cho, H., Lee, H.J., Heo, Y.K., Cho, Y., Gwon, Y.D., Kim, M.G., Park, K.H., Oh, Y.K., and Kim, Y.B. 2014. Immunogenicity of a trivalent human papillomavirus L1 DNA-encapsidated, non-replicable baculovirus nanovaccine. PLoS One9, e95961.
6. De Bruijn, M.L., Greenstone, H.L., Vermeulen, H., Melief, C.J., Lowy, D.R., Schiller, J.T., and Kast, W.M. 1998. L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology250, 371–376.
7. Dupuy, C., Buzoni-Gatel, D., Touze, A., Bout, D., and Coursaget, P. 1999. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J. Virol.73, 9063–9071.
8. Einstein, M.H., Kadish, A.S., Burk, R.D., Kim, M.Y., Wadler, S., Streicher, H., Goldberg, G.L., and Runowicz, C.D. 2007. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol. Oncol.106, 453–460.
9. Gan, L., Jia, R., Zhou, L., Guo, J., and Fan, M. 2014. Fusion of CTLA-4 with HPV16 E7 and E6 enhanced the potency of therapeutic HPV DNA vaccine. PLoS One9, e108892.
10. Garcia Paz, F., Madrid Marina, V., Morales Ortega, A., Santander Gonzalez, A., Peralta Zaragoza, O., Burguete Garcia, A., Torres Poveda, K., Moreno, J., Alcocer Gonzalez, J., Hernandez Marquez, E., et al. 2014. The relationship between the antitumor effect of the IL-12 gene therapy and the expression of Th1 cytokines in an HPV16-positive murine tumor model. Med. Inflamm.2014, 510846.
11. Kawana, K., Adachi, K., Kojima, S., Kozuma, S., and Fujii, T. 2012.Therapeutic human papillomavirus (HPV) Vaccines: A novel approach. Open Virol. J.6, 264–269.
12. Kenter, G.G., Welters, M.J., Valentijn, A.R., Lowik, M.J., Berendsvan der Meer, D.M., Vloon, A.P., Essahsah, F., Fathers, L.M., Offringa, R., Drijfhout, J.W., et al. 2009. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl. J. Med.361, 1838–1847.
13. Kim, Y.J., Kwon, M.J., Woo, H.Y., and Paik, S.Y. 2013. Prevalence of human papillomavirus infection and genotype distribution determined by the cyclic-catcher melting temperature analysis in Korean medical checkup population. J. Microbiol.51, 665–670.
14. Kwag, H.L., Kim, H.J., and Chang, D.Y. 2012. The production and immunogenicity of human papillomavirus type 58 virus-like particles produced in Saccharomyces cerevisiae. J. Microbiol.50, 813–820.
15. Lee, H.J., Hur, Y.K., Cho, Y.D., Kim, M.G., Lee, H.T., Oh, Y.K., and Kim, Y.B. 2012. Immunogenicity of bivalent human papillomavirus DNA vaccine using human endogenous retrovirus envelope-coated baculoviral vectors in mice and pigs. PLoS One7, e50296.
16. Lee, H.J., Park, N., Cho, H.J., Yoon, J.K., Van, N.D., Oh, Y.K., and Kim, Y.B. 2010. Development of a novel viral DNA vaccine against human papillomavirus: AcHERV-HP16L1. Vaccine28, 1613–1619.
17. Lehtinen, M. and Dillner, J. 2013. Clinical trials of human papillomavirus vaccines and beyond. Nat. Rev. Clin. Oncol.10, 400–410.
18. Li, Y.L., Qiu, X.H., Shen, C., Liu, J.N., and Zhang, J. 2010. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors. Oncol. Reports24, 1323–1329.
19. Lu, B., Kumar, A., Castellsague, X., and Giuliano, A.R. 2011. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & metaanalysis. BMC Infect. Dis. 11, 13.
20. Luo, W.Y., Lin, S.Y., Lo, K.W., Lu, C.H., Hung, C.L., Chen, C.Y., Chang, C.C., and Hu, Y.C. 2013. Adaptive immune responses elicited by baculovirus and impacts on subsequent transgene expression in vivo. J. Virol.87, 4965–4973.
21. Ma, B., Maraj, B., Tran, N.P., Knoff, J., Chen, A., Alvarez, R.D., Hung, C.F., and Wu, T.C. 2012. Emerging human papillomavirus vaccines. Expert Opin. Emerg. Drugs17, 469–492.
22. Monie, A., Tsen, S.W., Hung, C.F., and Wu, T.C. 2009. Therapeutic HPV DNA vaccines. Expert Rev. Vaccines8, 1221–1235.
23. Ohlschlager, P., Osen, W., Dell, K., Faath, S., Garcea, R.L., Jochmus, I., Muller, M., Pawlita, M., Schafer, K., Sehr, P., et al. 2003. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J. Virol.77, 4635–4645.
24. Revaz, V., Benyacoub, J., Kast, W.M., Schiller, J.T., De Grandi, P., and Nardelli-Haefliger, D. 2001. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice. Virology279, 354–360.
25. Romanowski, B. 2011. Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines. Human Vaccines7, 161–169.
26. Rudolf, M.P., Fausch, S.C., Da Silva, D.M., and Kast, W.M. 2001. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J. Immunol.166, 5917–5924.
27. Schafer, K., Muller, M., Faath, S., Henn, A., Osen, W., Zentgraf, H., Benner, A., Gissmann, L., and Jochmus, I. 1999. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int. J. Cancer81, 881–888.
28. Sharma, C., Dey, B., Wahiduzzaman, M., and Singh, N. 2012. Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer. Vaccine30, 5417–5424.
29. Trimble, C.L. and Frazer, I.H. 2009. Development of therapeutic HPV vaccines. Lancet Oncol.10, 975–980.
30. Xu, Y.F., Zhang, Y.Q., Xu, X.M., and Song, G.X. 2006. Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes. Arch. Virol.151, 2133–2148.
31. Zheng, Y., Zhang, Y., Ma, Y., Wan, J., Shi, C., and Huang, L. 2008. Enhancement of immunotherapeutic effects of HPV16E7 on cervical cancer by fusion with CTLA4 extracellular region. J. Microbiol.46, 728–736.